WV HB3344

Establishes a grant program administered by the Secretary of Health to fund FDA drug development trials for ibogaine as a treatment for opioid use disorder, co-occurring substance use disorders, and other neurological or mental health conditions

Requires grant applicants to be corporate entities capable of conducting FDA trials, with detailed proposals including trial design, cardiac safety protocols, participant recruitment plans, and matching funds equal to the grant amount

Creates a selection committee composed of subject matter experts, philanthropic partners, and legislative designees to review applications and recommend the best candidate to conduct the trials

Mandates the selected applicant submit an Investigational New Drug (IND) application to the FDA and seek breakthrough therapy designation for ibogaine under 21 U.S.C. Section 356

Requires applicants to propose plans for establishing corporate presence in West Virginia, securing insurance coverage (including Medicare, Medicaid, and TRICARE), ensuring access for uninsured individuals, and training medical providers to administer ibogaine treatment